ArticlePloS one2013
Human IgG subclasses against enterovirus Type 71: neutralization versus antibody dependent enhancement of infection.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 54 citations in OpenAlex.
- Analysis on the characteristics of delayed EV71 vaccination among children in the birth cohort from 2017 to 2022.Human vaccines & immunotherapeutics · 2026Article
- Review
- Enterovirus A71 priorities, challenges, and future opportunities in humoral immunity and vaccine development.NPJ vaccines · 2025Review
- Understanding the Immune System's Intricate Balance: Activation, Tolerance, and Self-Protection.International journal of molecular sciences · 2025Review
- From Monovalent to Multivalent Vaccines, the Exploration for Potential Preventive Strategies Against Hand, Foot, and Mouth Disease (HFMD).Virologica Sinica · 2021Review
- Specific Antibody Deficiency in Adult Patients With IgG or IgG Subclass Deficiency.Allergy, asthma & immunology research · 2021Article
- Self-Assembled Multi-Epitope Peptide Amphiphiles Enhance the Immune Response against Enterovirus 71.Nanomaterials (Basel, Switzerland) · 2020Article
- Interplays between Enterovirus A71 and the innate immune system.Journal of biomedical science · 2019Review
- Human DC-SIGN and CD23 do not interact with human IgG.Scientific reports · 2019Article
- Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery.Scientific reports · 2019Article
- Advances in Antigenic Peptide-Based Vaccine and Neutralizing Antibodies against Viruses Causing Hand, Foot, and Mouth Disease.International journal of molecular sciences · 2019Review
- Immunocompetent and Immunodeficient Mouse Models for Enterovirus 71 Pathogenesis and Therapy.Viruses · 2018Review
- Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Review
- Structure, Immunogenicity, and Protective Mechanism of an Engineered Enterovirus 71-Like Particle Vaccine Mimicking 80S Empty Capsid.Journal of virology · 2018Article
- Errors in data interpretation from genetic variation of human analytes.JCI insight · 2017Article
- Protective antibodies against Clostridium difficile are present in intravenous immunoglobulin and are retained in humans following its administration.Clinical and experimental immunology · 2017Article
- Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection.EBioMedicine · 2017Article
- A Novel Enterovirus 71 (EV71) Virulence Determinant: The 69th Residue of 3C Protease Modulates Pathogenicity.Frontiers in cellular and infection microbiology · 2017Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emerging human enterovirus 71 (EV71) represents a growing threat to public health, and no vaccine or specific antiviral is currently available. Human intravenous immunoglobulin (IVIG) is clinical used in treating severe EV71 infections. However, the discovery of antibody dependent enhancement (ADE) of EV71 infection illustrates the complex roles of antibody in controlling EV71 infection. In this study, to identify the distinct role of each IgG subclass on neutralization and enhancement of EV71 infection, different lots of pharmaceutical IVIG preparations manufactured from Chinese donors were used for IgG subclass fractionation by pH gradient elution with the protein A-conjugated affinity column. The neutralization and ADE capacities on EV71 infection of each purified IgG subclass were then assayed, respectively. The neutralizing activity of human IVIG is mainly mediated by IgG1 subclass and to less extent by IgG2 subclass. Interestingly, IgG3 fraction did not have neutralizing activity but enhanced EV71 infection in vitro. These results revealed the different roles of human IgG subclasses on EV71 infection, which is of critical importance for the rational design of immunotherapy and vaccines against severe EV71 diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.